NeuroMab™ Anti-TDP43 BBB Shuttle Antibody(NRZP-1022-ZP2626)

Fig.1 depicts that TDP-0 antibody recognizes TDP-43 oligomers specifically.

The 1 ml SEC fractions were collected and subjected to dot blotting by TDP-0 (upper blot) and N -26o antibodies (lower blot).

Fig.2 depicts that TDP-43 oligomers are present in FTLD-TDP patients.

TDP-0 antibody, in contrast to antibodies for monomeric TDP-43, did not stain nuclei demonstrating specificity toward misfolded TDP-43. Scale bars in all panels are 20 μιη.

Fig.3 depicts that TDP-0 mAbs exhibit higher specificities toward TDP-43 oligomer.

Various concentrations of TDP-0 mAbs (1 -2 x 10"^g/mL) respectively produced by TDP-O-3, -5, -8, -9, and -10 hybridoma cells were used in ELISA assay to detect the SDS denatured or non-denatured TDP-43.

Fig.4 depicts that TDP-0 mAbs exhibit higher specificities toward purified TDP-43 oligomer.

Conditional medium of TDP-O-3, -5, -8, -9, and -10 hybridoma cell lines were used to detect the TDP-43 oligomers and monomers by ELISA assay.

Fig.5 depicts that TDP-0 monoclonal antibody rescues TDP-43 oligomers-induced cytotoxicity.

MTT assay was performed to examine cell viability of BE(2)-C cells. Data are presented as mean ± standard deviation. Statistical analysis was performed by one-way ANOVAs, *p< 0.05, **p< 0.01 , ***p< 0.001 . The result showed the toxicity induced by TDP-43 oligomers was significantly rescued by the treatment of TDP-0 antibody.

Fig.6 depicts that TDP-43 oligomers are present and increase with age in transgenic mouse model of FTLD-TDP.

Immunofluorescent staining of human TDP-43 and TDP-43 oligomers in the brain slices of wild type and 6- and 12-month-old TDP-43 Tg+/+ transgenic mice. Cells with anti-TDP oligomer staining, TDP-43 staining, and DAPI staining are shown (scale bar, 100 μιη). Blocked area was presented at higher magnification in the last column (scale bar, 25 μιη).